File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: HBsAg loss is higher among caucasians compared to Asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study)

TitleHBsAg loss is higher among caucasians compared to Asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study)
Authors
Issue Date2020
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting Digital Experience 2020, Boston, USA, 13-16 November 2020. In Hepatology, 2020, v. 72 n. S1, p. 19A-20A, abstract no. 23 How to Cite?
AbstractBackground: Despite several recent studies, the efficacy of finite nucleos(t)ide analogue (NA) therapy for CHB patients has not yet been well established due to contradictory findings and inadequate sample sizes. We aim to establish and describe a global, multi-center cohort of CHB patients who discontinued NA therapy, and evaluate outcomes following cessation of NA therapy. Methods: This is an on-going cohort study of CHB patients who discontinued NA therapy between 2000-2020 from 12 participating centers across North America, Europe and Asia. Patients coinfected with HIV, hepatitis C virus, hepatitis D virus, or those who received (peg)interferon treatment within a year prior to NA cessation were excluded. We analyzed retreatment and off-treatment HBsAg loss using multivariable logistic regression. Only HBeAg negative patients with undetectable HBV DNA at the time of NA cessation were included in this analysis. Results: Among 1,509 CHB patients who discontinued NA therapy (mean age 52.7±11.3 years, 72.4% male, 11.4% Caucasian, 86.5% Asian, 43.4% HBV genotype B), 70.5% were HBeAg negative, 16.8% were HBeAg positive, and 12.7% had unknown HBeAg status at start of NA therapy (SOT). Majority were treated with entecavir (ETV [51.7%]) or tenofovir disoproxil fumarate (TDF [28.6%]) prior to cessation. Total median follow-up time was 16.4 (IQR:6.9-31.6) months, median time to retreatment was 10.1 (IQR:5.6-19.8) months, and median time to HBsAg loss was 17.0 (IQR:11.4-32.0) months. Overall, 42.9% were retreated and 8.1% (n = 111) had HBsAg loss. Odds of retreatment were higher among Asians (vs. Caucasians: OR 1.7; 95% CI 1.1-2.6; p=0.03), and among those treated with ETV (vs. TDF: OR 1.5; 95% CI 1.1-1.9; p=0.006). Older age was also associated with higher odds of retreatment, and there were no significant differences in retreatment by SOT HBeAg status. Odds of HBsAg loss were higher among males (vs. females: OR 1.9; 95% CI 1.1-3.6; p=0.04), and among Caucasians (vs. Asians: OR 2.6; 95% CI 1.4-4.9; p=0.002). While not statistically significant, HBsAg loss was higher among SOT HBeAg positive patients, and among those treated with TDF (vs. ETV). There were 12 deaths during follow-up of which, 8 were liver-related. Conclusion: Odds of HBsAg loss after NA cessation were 2.6 times higher among Caucasians compared to Asians, and 1.9 times higher among males compared to females. There was also a trend towards higher HBsAg loss in those treated with TDF compared to those treated with ETV.
DescriptionOral Presentation - no. 23
Persistent Identifierhttp://hdl.handle.net/10722/305528
ISSN
2023 Impact Factor: 12.9
2023 SCImago Journal Rankings: 5.011
AwardAASLD Foundation Abstract Award Recipient

 

DC FieldValueLanguage
dc.contributor.authorHirode, G-
dc.contributor.authorChoi, HSJ-
dc.contributor.authorSu, TH-
dc.contributor.authorWong, GLH-
dc.contributor.authorSeto, WKW-
dc.contributor.authorHees, SV-
dc.contributor.authorPapatheodoridi, M-
dc.contributor.authorBrakenhoff, S-
dc.contributor.authorLens, S-
dc.contributor.authorSarowar, A-
dc.contributor.authorChien, RN-
dc.contributor.authorForns, X-
dc.contributor.authorSonneveld, MJ-
dc.contributor.authorPapatheodoridis, G-
dc.contributor.authorVanwolleghem, T-
dc.contributor.authorYuen, RMF-
dc.contributor.authorChan, HLY-
dc.contributor.authorKao, JH-
dc.contributor.authorHsu, YC-
dc.contributor.authorChen, CH-
dc.contributor.authorHansen, BE-
dc.contributor.authorCornberg, M-
dc.contributor.authorJeng, WJ-
dc.contributor.authorJanssen, HLA-
dc.contributor.authorRETRACT-B Study Group,-
dc.date.accessioned2021-10-20T10:10:40Z-
dc.date.available2021-10-20T10:10:40Z-
dc.date.issued2020-
dc.identifier.citationThe Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting Digital Experience 2020, Boston, USA, 13-16 November 2020. In Hepatology, 2020, v. 72 n. S1, p. 19A-20A, abstract no. 23-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/305528-
dc.descriptionOral Presentation - no. 23-
dc.description.abstractBackground: Despite several recent studies, the efficacy of finite nucleos(t)ide analogue (NA) therapy for CHB patients has not yet been well established due to contradictory findings and inadequate sample sizes. We aim to establish and describe a global, multi-center cohort of CHB patients who discontinued NA therapy, and evaluate outcomes following cessation of NA therapy. Methods: This is an on-going cohort study of CHB patients who discontinued NA therapy between 2000-2020 from 12 participating centers across North America, Europe and Asia. Patients coinfected with HIV, hepatitis C virus, hepatitis D virus, or those who received (peg)interferon treatment within a year prior to NA cessation were excluded. We analyzed retreatment and off-treatment HBsAg loss using multivariable logistic regression. Only HBeAg negative patients with undetectable HBV DNA at the time of NA cessation were included in this analysis. Results: Among 1,509 CHB patients who discontinued NA therapy (mean age 52.7±11.3 years, 72.4% male, 11.4% Caucasian, 86.5% Asian, 43.4% HBV genotype B), 70.5% were HBeAg negative, 16.8% were HBeAg positive, and 12.7% had unknown HBeAg status at start of NA therapy (SOT). Majority were treated with entecavir (ETV [51.7%]) or tenofovir disoproxil fumarate (TDF [28.6%]) prior to cessation. Total median follow-up time was 16.4 (IQR:6.9-31.6) months, median time to retreatment was 10.1 (IQR:5.6-19.8) months, and median time to HBsAg loss was 17.0 (IQR:11.4-32.0) months. Overall, 42.9% were retreated and 8.1% (n = 111) had HBsAg loss. Odds of retreatment were higher among Asians (vs. Caucasians: OR 1.7; 95% CI 1.1-2.6; p=0.03), and among those treated with ETV (vs. TDF: OR 1.5; 95% CI 1.1-1.9; p=0.006). Older age was also associated with higher odds of retreatment, and there were no significant differences in retreatment by SOT HBeAg status. Odds of HBsAg loss were higher among males (vs. females: OR 1.9; 95% CI 1.1-3.6; p=0.04), and among Caucasians (vs. Asians: OR 2.6; 95% CI 1.4-4.9; p=0.002). While not statistically significant, HBsAg loss was higher among SOT HBeAg positive patients, and among those treated with TDF (vs. ETV). There were 12 deaths during follow-up of which, 8 were liver-related. Conclusion: Odds of HBsAg loss after NA cessation were 2.6 times higher among Caucasians compared to Asians, and 1.9 times higher among males compared to females. There was also a trend towards higher HBsAg loss in those treated with TDF compared to those treated with ETV.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.relation.ispartofThe Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting Digital Experience 2020-
dc.titleHBsAg loss is higher among caucasians compared to Asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study)-
dc.typeConference_Paper-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.natureabstract-
dc.identifier.hkuros326660-
dc.identifier.volume72-
dc.identifier.issueS1-
dc.identifier.spage19A-
dc.identifier.epage20A-
dc.publisher.placeUnited States-
dc.description.awardAASLD Foundation Abstract Award Recipient-
dc.identifier.partofdoi10.1002/hep.31578-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats